Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle)

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1765, Issue 2, 2006, Pages 101-125

  Tardy, Claudine ^a   Codogno, Patrice ^b   Autefage, Hélène ^a   Levade, Thierry ^a   Andrieu Abadie, Nathalie ^a  

^a INSERM   (France)

^b INSTITUT ANDRÉ LWOFF   (France)

Author keywords

Apoptosis; Autophagy; Cathepsin; Hydrolase; Lysosome

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALPHA TOCOPHEROL SUCCINATE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; B 13; BAFILOMYCIN; BILE SALT; BLEOMYCIN; CA 074; CAMPTOTHECIN; CELL PROTEIN; CERAMIDE DERIVATIVE; CIPROFLOXACIN; CISPLATIN; CYSTEINE PROTEINASE INHIBITOR; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIBODY; FENRETINIDE; GAMMA INTERFERON; LEUCYLLEUCINE METHYL ESTER; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NAPHTHAZARIN; NORFLOXACIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SPHINGOSINE; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ACIDIFICATION; ACIDITY; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL CULTURE; CELL DEATH; CELL ORGANELLE; ENZYME ACTIVATION; HUMAN; LYSOSOME; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 33646128014     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2005.11.003     Document Type: Review

References (383)

1. de Duve C. Lysosomes revisited. Eur. J. Biochem. 137 (1983) 391-397
2. Dunn Jr. W.A. Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol. 4 (1994) 139-143
3. Cuervo A.M. Autophagy: many paths to the same end. Mol. Cell. Biochem. 263 (2004) 55-72
4. Majeski A.E., and Dice J.F. Mechanisms of chaperone-mediated autophagy. Int. J. Biochem. Cell Biol. 36 (2004) 2435-2444
5. Eskelinen E.L. Maturation of autophagic vacuoles in mammalian cells. Autophagy 1 (2005) 1-10
6. Dell'Angelica E.C., Mullins C., Caplan S., and Bonifacino J.S. Lysosome-related organelles. FASEB J. 14 (2000) 1265-1278
7. Blott E.J., and Griffiths G.M. Secretory lysosomes. Nat. Rev., Mol. Cell Biol. 3 (2002) 122-131
8. Stinchcombe J., Bossi G., and Griffiths G.M. Linking albinism and immunity: the secrets of secretory lysosomes. Science 305 (2004) 55-59
9. Kornfeld S. Trafficking of lysosomal enzymes in normal and disease states?. J. Clin. Invest. 77 (1986) 1-6
10. Kornfeld R., and Kornfeld S. Assembly of asparagine-linked oligosaccharides?. Annu. Rev. Biochem. 54 (1985) 631-664
11. von Figura K., and Hasilik A. Lysosomal enzymes and their receptors?. Annu. Rev. Biochem. 55 (1986) 167-193
12. Gonzalez-Noriega A., Grubb J.H., Talkad V., and Sly W.S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling?. J. Cell Biol. 85 (1980) 839-852
13. Lobel P., Dahms N.M., Breitmeyer J., Chirgwin J.M., and Kornfeld S. Cloning of the bovine 215-kDa cation-independent mannose 6-phosphate receptor. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 2233-2237
14. Lobel P., Dahms N.M., and Kornfeld S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor?. J. Biol. Chem. 263 (1988) 2563-2570
15. Dahms N.M., Lobel P., Breitmeyer J., Chirgwin J.M., and Kornfeld S. 46 kd mannose 6-phosphate receptor: cloning, expression, and homology to the 215 kd mannose 6-phosphate receptor. Cell 50 (1987) 181-192
16. Pohlmann R., Nagel G., Schmidt B., Stein M., Lorkowski G., Krentler C., Cully J., Meyer H.E., Grzeschik K.H., Mersmann G., et al. Cloning of a cDNA encoding the human cation-dependent mannose 6-phosphate-specific receptor. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5575-5579
17. Gabel C.A., Goldberg D.E., and Kornfeld S. Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal enzyme targeting. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 775-779
18. Nolan C.M., Creek K.E., Grubb J.H., and Sly W.S. Antibody to the phosphomannosyl receptor inhibits recycling of receptor in fibroblasts. J. Cell. Biochem. 35 (1987) 137-151
19. Stein M., Zijderhand-Bleekemolen J.E., Geuze H., Hasilik A., and von Figura K. Mr 46,000 mannose 6-phosphate specific receptor: its role in targeting of lysosomal enzymes. EMBO J. 6 (1987) 2677-2681
20. Kyle J.W., Nolan C.M., Oshima A., and Sly W.S. Expression of human cation-independent mannose 6-phosphate receptor cDNA in receptor-negative mouse P388D1 cells following gene transfer?. J. Biol. Chem. 263 (1988) 16230-16235
21. Lobel P., Fujimoto K., Ye R.D., Griffiths G., and Kornfeld S. Mutations in the cytoplasmic domain of the 275 kd mannose 6-phosphate receptor differentially alter lysosomal enzyme sorting and endocytosis. Cell 57 (1989) 787-796
22. Ma Z.M., Grubb J.H., and Sly W.S. Cloning, sequencing, and functional characterization of the murine 46-kDa mannose 6-phosphate receptor?. J. Biol. Chem. 266 (1991) 10589-10595
23. Koster A., Saftig P., Matzner U., von Figura K., Peters C., and Pohlmann R. Targeted disruption of the M(r) 46,000 mannose 6-phosphate receptor gene in mice results in misrouting of lysosomal proteins. EMBO J. 12 (1993) 5219-5223
24. Ludwig T., Ovitt C.E., Bauer U., Hollinshead M., Remmler J., Lobel P., Ruther U., and Hoflack B. Targeted disruption of the mouse cation-dependent mannose 6-phosphate receptor results in partial missorting of multiple lysosomal enzymes. EMBO J. 12 (1993) 5225-5235
25. Dennis P.A., and Rifkin D.B. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 580-584
26. Godar S., Horejsi V., Weidle U.H., Binder B.R., Hansmann C., and Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur. J. Immunol. 29 (1999) 1004-1013
27. Ghahary A., Tredget E.E., Mi L., and Yang L. Cellular response to latent TGF-beta1 is facilitated by insulin-like growth factor-II/mannose-6-phosphate receptors on MS-9 cells. Exp. Cell Res. 251 (1999) 111-120
28. Motyka B., Korbutt G., Pinkoski M.J., Heibein J.A., Caputo A., Hobman M., Barry M., Shostak I., Sawchuk T., Holmes C.F., Gauldie J., and Bleackley R.C. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103 (2000) 491-500
29. Lau M.M., Stewart C.E., Liu Z., Bhatt H., Rotwein P., and Stewart C.L. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev. 8 (1994) 2953-2963
30. Wang Z.Q., Fung M.R., Barlow D.P., and Wagner E.F. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 372 (1994) 464-467
31. Sohar I., Sleat D., Gong Liu C., Ludwig T., and Lobel P. Mouse mutants lacking the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor are impaired in lysosomal enzyme transport: comparison of cation-independent and cation-dependent mannose 6-phosphate receptor-deficient mice. Biochem. J. 330 (1998) 903-908
32. Kang J.X., Li Y., and Leaf A. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13671-13676
33. Kang J.X., Bell J., Leaf A., Beard R.L., and Chandraratna R.A. Retinoic acid alters the intracellular trafficking of the mannose-6-phosphate/insulin-like growth factor II receptor and lysosomal enzymes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13687-13691
34. Kang J.X., Bell J., Beard R.L., and Chandraratna R.A. Mannose 6-phosphate/insulin-like growth factor II receptor mediates the growth-inhibitory effects of retinoids. Cell Growth Differ 10 (1999) 591-600
35. Leksa V., Godar S., Cebecauer M., Hilgert I., Breuss J., Weidle U.H., Horejsi V., Binder B.R., and Stockinger H. The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration?. J. Biol. Chem. 277 (2002) 40575-40582
36. Nykjaer A., Christensen E.I., Vorum H., Hager H., Petersen C.M., Roigaard H., Min H.Y., Vilhardt F., Moller L.B., Kornfeld S., and Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction?. J. Cell Biol. 141 (1998) 815-828
37. Ellis R.E., Yuan J.Y., and Horvitz H.R. Mechanisms and functions of cell death?. Annu. Rev. Cell Biol. 7 (1991) 663-698
38. Schwartz L.M. The role of cell death genes during development. Bioessays 13 (1991) 389-395
39. Schweichel J.U., and Merker H.J. The morphology of various types of cell death in prenatal tissues. Teratology 7 (1973) 253-266
40. Clarke P.G. Developmental cell death: morphological diversity and multiple mechanisms. Anat. Embryol. (Berl.) 181 (1990) 195-213
41. Kroemer G., El-Deiry W.S., Golstein P., Peter M.E., Vaux D., Vandenabeele P., Zhivotovsky B., Blagosklonny M.V., Malorni W., Knight R.A., Piacentini M., Nagata S., and Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 12 Suppl. 2 (2005) 1463-1467
42. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26 (1972) 239-257
43. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23 (2004) 2746-2756
44. Saraste A. Morphologic criteria and detection of apoptosis. Herz 24 (1999) 189-195
45. Sansonetti P.J. Phagocytosis, a cell biology view?. J. Cell Sci. 113 (2000) 3355-3356
46. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
47. Rathmell J.C., and Thompson C.B. The central effectors of cell death in the immune system?. Annu. Rev. Immunol. 17 (1999) 781-828
48. Siegel R.M., Chan F.K., Chun H.J., and Lenardo M.J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1 (2000) 469-474
49. Thorburn A. Death receptor-induced cell killing. Cell Signal. 16 (2004) 139-144
50. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
51. Jiang X., and Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1?. J. Biol. Chem. 275 (2000) 31199-31203
52. Halestrap A.P., Dor E., Gillespie J.P., and O'Toole A. Mitochondria and cell death. Biochem. Soc. Trans. 28 (2000) 170-177
53. Halestrap A.P., Gillespie J.P., O'Toole A., and Doran E. Mitochondria and cell death: a pore way to die?. Symp. Soc. Exp. Biol. 52 (2000) 65-80
54. Shintani T., and Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 306 (2004) 990-995
55. Lum J.J., DeBerardinis R.J., and Thompson C.B. Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev., Mol. Cell Biol. 6 (2005) 439-448
56. Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 120 (2005) 159-162
57. Bursch W. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ. 8 (2001) 569-581
58. Lockshin R.A., and Zakeri Z. Apoptosis, autophagy, and more. Int. J. Biochem. Cell Biol. 36 (2004) 2405-2419
59. Baehrecke E.H. Autophagy: dual roles in life and death?. Nat. Rev., Mol. Cell Biol. 6 (2005) 505-510
60. Debnath J., Baehrecke E.H., and Kroemer G. Does autophagy contribute to cell death?. Autophagy 2 (2005) 10-18
61. Golstein P., and Kroemer G. Redundant cell death mechanisms as relics and backups. Cell Death Differ. 12 Suppl. 2 (2005) 1490-1496
62. Kroemer G., and Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev., Cancer 5 (2005) 886-897
63. Levine B., and Yuan J. Autophagy in cell death: an innocent convict?. J. Clin. Invest. 115 (2005) 2679-2688
64. Mortimore G.E., and Kadowaki M. In: Ciechanover A.J., and Schwartz A.L. (Eds). Cellular Proteolytic Systems (1994), Wiley-Liss, New York, NY 65-87
65. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., Ohsumi Y., Tokuhisa T., and Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 432 (2004) 1032-1036
66. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., and Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248
67. Boya P., Gonzalez-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., Metivier D., Meley D., Souquere S., Yoshimori T., Pierron G., Codogno P., and Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25 (2005) 1025-1040
68. Liu Y., Schiff M., Czymmek K., Talloczy Z., Levine B., and Dinesh-Kumar S.P. Autophagy regulates programmed cell death during the plant innate immune response. Cell 121 (2005) 567-577
69. Bursch W., Ellinger A., Gerner C., Frohwein U., and Schulte-Hermann R. Programmed cell death (PCD). Apoptosis, autophagic PCD, or others?. Ann. N. Y. Acad. Sci. 926 (2000) 1-12
70. Gozuacik D., and Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23 (2004) 2891-2906
71. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. Arch. Histol. Cytol. 64 (2001) 233-246
72. Cuervo A.M. Autophagy: in sickness and in health. Trends Cell Biol. 14 (2004) 70-77
73. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16 (2004) 663-669
74. Yu L., Alva A., Su H., Dutt P., Freundt E., Welsh S., Baehrecke E.H., and Lenardo M.J. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304 (2004) 1500-1502
75. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., and Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6 (2004) 1221-1228
76. Thorburn J., Moore F., Rao A., Barclay W.W., Thomas L.R., Grant K.W., Cramer S.D., and Thorburn A. Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol. Biol. Cell 16 (2005) 1189-1199
77. Scarlatti F., Bauvy C., Ventruti A., Sala G., Cluzeaud F., Vandewalle A., Ghidoni R., and Codogno P. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279 (2004) 18384-18391
78. Inbal B., Bialik S., Sabanay I., Shani G., and Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J. Cell Biol. 157 (2002) 455-468
79. Liang X.H., Kleeman L.K., Jiang H.H., Gordon G., Goldman J.E., Berry G., Herman B., and Levine B. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J. Virol. 72 (1998) 8586-8596
80. Pyo J.O., Jang M.H., Kwon Y.K., Lee H.J., Jun J.I., Woo H.N., Cho D.H., Choi B., Lee H., Kim J.H., Mizushima N., Oshumi Y., and Jung Y.K. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J. Biol. Chem. 280 (2005) 20722-20729
81. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., and Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122 (2005) 927-939
82. Castino R., Demoz M., and Isidoro C. Destination 'lysosome': a target organelle for tumour cell killing?. J. Mol. Recognit. 16 (2003) 337-348
83. Codogno P., and Meijer A.J. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12 Suppl. 2 (2005) 1509-1518
84. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
85. Croall D.E., and McGrody K.S. Domain structure of calpain: mapping the binding site for calpastatin. Biochemistry 33 (1994) 13223-13230
86. Johnson D.E. Noncaspase proteases in apoptosis. Leukemia 14 (2000) 1695-1703
87. Yang Y., and Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17 (2003) 790-799
88. Zhang H.G., Wang J., Yang X., Hsu H.C., and Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23 (2004) 2009-2015
89. Friedman J., and Xue D. To live or die by the sword: the regulation of apoptosis by the proteasome. Dev. Cell 6 (2004) 460-461
90. Heusel J.W., Wesselschmidt R.L., Shresta S., Russell J.H., and Ley T.J. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76 (1994) 977-987
91. Adrain C., Murphy B.M., and Martin S.J. Molecular ordering of the caspase activation cascade initiated by the CTL/NK protease granzyme B. J. Biol. Chem. 280 (2005) 4663-4673
92. Waterhouse N.J., Sedelies K.A., Brown K.A., Wowk M.E., Newbold A., Sutton V.R., Clarke C.J., Oliaro J., Lindemann R.K., Bird P.I., Johnstone R.W., and Trapani J.A. A central role for Bid in granzyme B-induced apoptosis. J. Biol. Chem. 280 (2005) 4476-4482
93. Lieberman J., and Fan Z. Nuclear war: the granzyme A-bomb. Curr. Opin. Immunol. 15 (2003) 553-559
94. Wright S.C., Zheng H., and Zhong J. Tumor cell resistance to apoptosis due to a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24). FASEB J. 10 (1996) 325-332
95. Miller D.K., Griffiths E., Lenard J., and Firestone R.A. Cell killing by lysosomotropic detergents. J. Cell Biol. 97 (1983) 1841-1851
96. Brunk U.T., Dalen H., Roberg K., and Hellquist H.B. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic. Biol. Med. 23 (1997) 616-626
97. Terman A., Neuzil J., Kagedal K., Ollinger K., and Brunk U.T. Decreased apoptotic response of inclusion-cell disease fibroblasts: a consequence of lysosomal enzyme missorting?. Exp. Cell Res. 274 (2002) 9-15
98. Tardy C., Tyynela J., Hasilik A., Levade T., and Andrieu-Abadie N. Stress-induced apoptosis is impaired in cells with a lysosomal targeting defect but is not affected in cells synthesizing a catalytically inactive cathepsin D. Cell Death Differ. 10 (2003) 1090-1100
99. Turk B., Turk D., and Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477 (2000) 98-111
100. Turk B., Turk V., and Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 378 (1997) 141-150
101. Guncar G., Pungercic G., Klemencic I., Turk V., and Turk D. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18 (1999) 793-803
102. Kirschke H., Barrett A.J., and Rawlings N.D. Proteinases 1: lysosomal cysteine proteinases. Protein Profile 2 (1995) 1581-1643
103. Guicciardi M.E., Deussing J., Miyoshi H., Bronk S.F., Svingen P.A., Peters C., Kaufmann S.H., and Gores G.J. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest. 106 (2000) 1127-1137
104. Foghsgaard L., Wissing D., Mauch D., Lademann U., Bastholm L., Boes M., Elling F., Leist M., and Jaattela M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153 (2001) 999-1010
105. Mathiasen I.S., Hansen C.M., Foghsgaard L., and Jaattela M. Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B. Int. J. Cancer 93 (2001) 224-231
106. Taha T.A., Kitatani K., Bielawski J., Cho W., Hannun Y.A., and Obeid L.M. TNF induces the loss of sphingosine kinase-1 by a cathepsin B dependent mechanism. J. Biol. Chem. 280 (2005) 17196-17202
107. Fehrenbacher N., Gyrd-Hansen M., Poulsen B., Felbor U., Kallunki T., Boes M., Weber E., Leist M., and Jaattela M. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 64 (2004) 5301-5310
108. Taha T.A., Osta W., Kozhaya L., Bielawski J., Johnson K.R., Gillanders W.E., Dbaibo G.S., Hannun Y.A., and Obeid L.M. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J. Biol. Chem. 279 (2004) 20546-20554
109. Roberts L.R., Kurosawa H., Bronk S.F., Fesmier P.J., Agellon L.B., Leung W.Y., Mao F., and Gores G.J. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 113 (1997) 1714-1726
110. Faubion W.A., Guicciardi M.E., Miyoshi H., Bronk S.F., Roberts P.J., Svingen P.A., Kaufmann S.H., and Gores G.J. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103 (1999) 137-145
111. Baskin-Bey E.S., Canbay A., Bronk S.F., Werneburg N., Guicciardi M.E., Nyberg S.L., and Gores G.J. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am. J. Physiol.: Gastrointest. Liver Physiol. 288 (2005) G396-G402
112. Fedorowski A., Steciwko A., and Rabczynski J. Serum cathepsin B activity during regression of Morris hepatoma 5123 D. Med. Sci. Monit. 10 (2004) BR144-BR150
113. Broker L.E., Huisman C., Span S.W., Rodriguez J.A., Kruyt F.A., and Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res. 64 (2004) 27-30
114. Jones B., Roberts P.J., Faubion W.A., Kominami E., and Gores G.J. Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am. J. Physiol. 275 (1998) G723-G730
115. Yamashima T., Kohda Y., Tsuchiya K., Ueno T., Yamashita J., Yoshioka T., and Kominami E. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'. Eur. J. Neurosci. 10 (1998) 1723-1733
116. Tsuchiya K., Kohda Y., Yoshida M., Zhao L., Ueno T., Yamashita J., Yoshioka T., Kominami E., and Yamashima T. Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. Exp. Neurol. 155 (1999) 187-194
117. Castino R., Pace D., Demoz M., Gargiulo M., Ariatta C., Raiteri E., and Isidoro C. Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas. Int. J. Cancer 97 (2002) 775-779
118. Tardy C., Autefage H., Garcia V., Levade T., and Andrieu-Abadie N. Mannose 6-phosphorylated proteins are required for tumor necrosis factor-induced apoptosis: defective response in I-cell disease fibroblasts. J. Biol. Chem. 279 (2004) 52914-52923
119. Zhu D.M., and Uckun F.M. Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells. Leuk. Lymphoma 39 (2000) 343-354
120. Zhu D.M., and Uckun F.M. Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis in human cancer cells. Clin. Cancer Res. 6 (2000) 2064-2069
121. Joyce J.A., and Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3 (2004) 1516-1619
122. Kummer J.A., Kamp A.M., Citarella F., Horrevoets A.J., and Hack C.E. Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C. J. Biol. Chem. 271 (1996) 9281-9286
123. Pham C.T., and Ley T.J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8627-8632
124. Pham C.T., Thomas D.A., Mercer J.D., and Ley T.J. Production of fully active recombinant murine granzyme B in yeast. J. Biol. Chem. 273 (1998) 1629-1633
125. Zhivotovsky B., Burgess D.H., Vanags D.M., and Orrenius S. Involvement of cellular proteolytic machinery in apoptosis. Biochem. Biophys. Res. Commun. 230 (1997) 481-488
126. Darmon A.J., Nicholson D.W., and Bleackley R.C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377 (1995) 446-448
127. Salvesen G.S., and Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell 91 (1997) 443-446
128. Bol B., and Campbell V. Abeta-mediated activation of the apoptotic cascade in cultured cortical neurones: a role for cathepsin-L. Neurobiol. Aging 25 (2004) 83-91
129. Welss T., Sun J., Irving J.A., Blum R., Smith A.I., Whisstock J.C., Pike R.N., von Mikecz A., Ruzicka T., Bird P.I., and Abts H.F. Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 42 (2003) 7381-7389
130. Levicar N., Dewey R.A., Daley E., Bates T.E., Davies D., Kos J., Pilkington G.J., and Lah T.T. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 10 (2003) 141-151
131. Barrett A.J., and Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 80 Pt. C (1981) 535-561
132. Reid W.A., Valler M.J., and Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J. Clin. Pathol. 39 (1986) 1323-1330
133. Tang J., and Wong R.N. Evolution in the structure and function of aspartic proteases. J. Cell. Biochem. 33 (1987) 53-63
134. Hasilik A., and Neufeld E.F. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J. Biol. Chem. 255 (1980) 4946-4950
135. Wu G.S., Saftig P., Peters C., and El-Deiry W.S. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16 (1998) 2177-2183
136. Neuzil J., Zhao M., Ostermann G., Sticha M., Gellert N., Weber C., Eaton J.W., and Brunk U.T. Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem. J. 362 (2002) 709-715
137. Deiss L.P., Galinka H., Berissi H., Cohen O., and Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J. 15 (1996) 3861-3870
138. Emert-Sedlak L., Shangary S., Rabinovitz A., Miranda M.B., Delach S.M., and Johnson D.E. Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Mol. Cancer Ther. 4 (2005) 733-742
139. Shibata M., Kanamori S., Isahara K., Ohsawa Y., Konishi A., Kametaka S., Watanabe T., Ebisu S., Ishido K., Kominami E., and Uchiyama Y. Participation of cathepsins B and D in apoptosis of PC12 cells following serum deprivation. Biochem. Biophys. Res. Commun. 251 (1998) 199-203
140. Roberg K., Kagedal K., and Ollinger K. Microinjection of cathepsin d induces caspase-dependent apoptosis in fibroblasts. Am. J. Pathol. 161 (2002) 89-96
141. Demoz M., Castino R., Cesaro P., Baccino F.M., Bonelli G., and Isidoro C. Endosomal-lysosomal proteolysis mediates death signalling by TNFalpha, not by etoposide, in L929 fibrosarcoma cells: evidence for an active role of cathepsin D. Biol. Chem. 383 (2002) 1237-1248
142. Heinrich M., Neumeyer J., Jakob M., Hallas C., Tchikov V., Winoto-Morbach S., Wickel M., Schneider-Brachert W., Trauzold A., Hethke A., and Schutze S. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ. 11 (2004) 550-563
143. Roberts L.R., Adjei P.N., and Gores G.J. Cathepsins as effector proteases in hepatocyte apoptosis. Cell Biochem. Biophys. 30 (1999) 71-88
144. Roberg K., and Ollinger K. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am. J. Pathol. 152 (1998) 1151-1156
145. Ollinger K. Inhibition of cathepsin D prevents free-radical-induced apoptosis in rat cardiomyocytes. Arch. Biochem. Biophys. 373 (2000) 346-351
146. Takuma K., Kiriu M., Mori K., Lee E., Enomoto R., Baba A., and Matsuda T. Roles of cathepsins in reperfusion-induced apoptosis in cultured astrocytes. Neurochem. Int. 42 (2003) 153-159
147. Yin L., Stearns R., and Gonzalez-Flecha B. Lysosomal and mitochondrial pathways in H2O2-induced apoptosis of alveolar type II cells. J. Cell. Biochem. 94 (2005) 433-445
148. Johansson A.C., Steen H., Ollinger K., and Roberg K. Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporine. Cell Death Differ. 10 (2003) 1253-1259
149. Zang Y., Beard R.L., Chandraratna R.A., and Kang J.X. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ. 8 (2001) 477-485
150. Kagedal K., Zhao M., Svensson I., and Brunk U.T. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem. J. 359 (2001) 335-343
151. Li X., Rayford H., Shu R., Zhuang J., and Uhal B.D. Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells. Am. J. Physiol.: Lung Cell. Mol. Physiol. 287 (2004) L46-L51
152. Thibodeau M.S., Giardina C., Knecht D.A., Helble J., and Hubbard A.K. Silica-induced apoptosis in mouse alveolar macrophages is initiated by lysosomal enzyme activity. Toxicol. Sci. 80 (2004) 34-48
153. Heinrich M., Wickel M., Schneider-Brachert W., Sandberg C., Gahr J., Schwandner R., Weber T., Saftig P., Peters C., Brunner J., Kronke M., and Schutze S. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18 (1999) 5252-5263
154. Reiners Jr. J.J., Caruso J.A., Mathieu P., Chelladurai B., Yin X.M., and Kessel D. Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage. Cell Death Differ. 9 (2002) 934-944
155. Isahara K., Ohsawa Y., Kanamori S., Shibata M., Waguri S., Sato N., Gotow T., Watanabe T., Momoi T., Urase K., Kominami E., and Uchiyama Y. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neuroscience 91 (1999) 233-249
156. Santana P., Pena L.A., Haimovitz-Friedman A., Martin S., Green D., McLoughlin M., Cordon-Cardo C., Schuchman E.H., Fuks Z., and Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86 (1996) 189-199
157. Vit J.P., and Rosselli F. Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 22 (2003) 8645-8652
158. Zhang Y., Mattjus P., Schmid P.C., Dong Z., Zhong S., Ma W.Y., Brown R.E., Bode A.M., and Schmid H.H. Involvement of the acid sphingomyelinase pathway in uva-induced apoptosis. J. Biol. Chem. 276 (2001) 11775-11782
159. Kashkar H., Wiegmann K., Yazdanpanah B., Haubert D., and Kroenke M. Acid sphingomyelinase is indispensable for UV-induced bax conformational change at the mitochondrial membrane. J. Biol. Chem. 280 (2005) 20804-20813
160. Komatsu M., Takahashi T., Abe T., Takahashi I., Ida H., and Takada G. Evidence for the association of ultraviolet-C and H(2)O(2)-induced apoptosis with acid sphingomyelinase activation. Biochim. Biophys. Acta 1533 (2001) 47-54
161. Separovic D., Pink J.J., Oleinick N.A., Kester M., Boothman D.A., McLoughlin M., Pena L.A., and Haimovitz-Friedman A. Niemann-Pick human lymphoblasts are resistant to phthalocyanine 4-photodynamic therapy-induced apoptosis. Biochem. Biophys. Res. Commun. 258 (1999) 506-512
162. Cifone M.G., Roncaioli P., De Maria R., Camarda G., Santoni A., Ruberti G., and Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14 (1995) 5859-5868
163. De Maria R., Rippo M.R., Schuchman E.H., and Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med. 187 (1998) 897-902
164. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., Kolesnick R., and Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276 (2001) 20589-20596
165. Haimovitz-Friedman A., Cordon-Cardo C., Bayoumy S., Garzotto M., McLoughlin M., Gallily R., Edwards III C.K., Schuchman E.H., Fuks Z., and Kolesnick R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 186 (1997) 1831-1841
166. Sawada M., Nakashima S., Kiyono T., Yamada J., Hara S., Nakagawa M., Shinoda J., and Sakai N. Acid sphingomyelinase activation requires caspase-8 but not p53 nor reactive oxygen species during Fas-induced apoptosis in human glioma cells. Exp. Cell Res. 273 (2002) 157-168
167. Colell A., Morales A., Fernandez-Checa J.C., and Garcia-Ruiz C. Ceramide generated by acidic sphingomyelinase contributes to tumor necrosis factor-alpha-mediated apoptosis in human colon HT-29 cells through glycosphingolipids formation. Possible role of ganglioside GD3. FEBS Lett. 526 (2002) 135-141
168. Cock J.G., Tepper A.D., de Vries E., van Blitterswijk W.J., and Borst J. CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase. J. Biol. Chem. 273 (1998) 7560-7565
169. Bezombes C., Segui B., Cuvillier O., Bruno A.P., Uro-Coste E., Gouaze V., Andrieu-Abadie N., Carpentier S., Laurent G., Salvayre R., Jaffrezou J.P., and Levade T. Lysosomal sphingomyelinase is not solicited for apoptosis signaling. FASEB J. 15 (2001) 297-299
170. Lin T., Genestier L., Pinkoski M.J., Castro A., Nicholas S., Mogil R., Paris F., Fuks Z., Schuchman E.H., Kolesnick R.N., and Green D.R. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J. Biol. Chem. 275 (2000) 8657-8663
171. Chiu S.M., Davis T.W., Meyers M., Ahmad N., Mukhtar H., and Separovic D. Phthalocyanine 4-photodynamic therapy induces ceramide generation and apoptosis in acid sphingomyelinase-deficient mouse embryonic fibroblasts. Int. J. Oncol. 16 (2000) 423-427
172. Nix M., and Stoffel W. Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation. Cell Death Differ. 7 (2000) 413-424
173. Schissel S.L., Keesler G.A., Schuchman E.H., Williams K.J., and Tabas I. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J. Biol. Chem. 273 (1998) 18250-18259
174. Rotolo J.A., Zhang J., Donepudi M., Lee H., Fuks Z., and Kolesnick R. Caspase-dependent and-independent activation of acid sphingomyelinase signaling. J. Biol. Chem. 280 (2005) 26425-26434
175. Cremesti A., Paris F., Grassme H., Holler N., Tschopp J., Fuks Z., Gulbins E., and Kolesnick R. Ceramide enables fas to cap and kill. J. Biol. Chem. 276 (2001) 23954-23961
176. Abdel Shakor A.B., Kwiatkowska K., and Sobota A. Cell surface ceramide generation precedes and controls FcgammaRII clustering and phosphorylation in rafts. J. Biol. Chem. 279 (2004) 36778-36787
177. Grassme H., Jendrossek V., Bock J., Riehle A., and Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 168 (2002) 298-307
178. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., Laurent G., Gambert P., Solary E., and Dimanche-Boitrel M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64 (2004) 3593-3598
179. Bezombes C., Grazide S., Garret C., Fabre C., Quillet-Mary A., Muller S., Jaffrezou J.P., and Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104 (2004) 1166-1173
180. Selzner M., Bielawska A., Morse M.A., Rudiger H.A., Sindram D., Hannun Y.A., and Clavien P.A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 61 (2001) 1233-1240
181. Samsel L., Zaidel G., Drumgoole H.M., Jelovac D., Drachenberg C., Rhee J.G., Brodie A.M., Bielawska A., and Smyth M.J. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58 (2004) 382-393
182. Raisova M., Goltz G., Bektas M., Bielawska A., Riebeling C., Hossini A.M., Eberle J., Hannun Y.A., Orfanos C.E., and Geilen C.C. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett. 516 (2002) 47-52
183. Strelow A., Bernardo K., Adam-Klages S., Linke T., Sandhoff K., Kronke M., and Adam D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J. Exp. Med. 192 (2000) 601-612
184. Kanto T., Kalinski P., Hunter O.C., Lotze M.T., and Amoscato A.A. Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167 (2001) 3773-3784
185. Burek C., Roth J., Koch H.G., Harzer K., Los M., and Schulze-Osthoff K. The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells. Oncogene 20 (2001) 6493-6502
186. Ségui B., Bezombes C., Uro-Coste E., Medin J.A., Andrieu-Abadie N., Auge N., Brouchet A., Laurent G., Salvayre R., Jaffrezou J.P., and Levade T. Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J. 14 (2000) 36-47
187. Hellsten E., Vesa J., Olkkonen V.M., Jalanko A., and Peltonen L. Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. EMBO J. 15 (1996) 5240-5245
188. Verkruyse L.A., and Hofmann S.L. Lysosomal targeting of palmitoyl-protein thioesterase. J. Biol. Chem. 271 (1996) 15831-15836
189. Camp L.A., and Hofmann S.L. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-Ras. J. Biol. Chem. 268 (1993) 22566-22574
190. Camp L.A., Verkruyse L.A., Afendis S.J., Slaughter C.A., and Hofmann S.L. Molecular cloning and expression of palmitoyl-protein thioesterase. J. Biol. Chem. 269 (1994) 23212-23219
191. Riikonen R., Vanhanen S.L., Tyynela J., Santavuori P., and Turpeinen U. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology 54 (2000) 1828-1832
192. Cho S., Dawson P.E., and Dawson G. Role of palmitoyl-protein thioesterase in cell death: implications for infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 5 Suppl. A (2001) 53-55
193. Mitchison H.M., and Mole S.E. Neurodegenerative disease: the neuronal ceroid lipofuscinoses (Batten disease). Curr. Opin. Neurol. 14 (2001) 795-803
194. Wisniewski K.E., Kida E., Golabek A.A., Kaczmarski W., Connell F., and Zhong N. Neuronal ceroid lipofuscinoses: classification and diagnosis. Adv. Genet. 45 (2001) 1-34
195. Zhang Z., Butler J.D., Levin S.W., Wisniewski K.E., Brooks S.S., and Mukherjee A.B. Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat. Med. 7 (2001) 478-484
196. Cho S., Dawson P.E., and Dawson G. Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells. J. Neurosci. Res. 62 (2000) 234-240
197. Dawson G., Dawson S.A., Marinzi C., and Dawson P.E. Anti-tumor promoting effects of palmitoyl: protein thioesterase inhibitors against a human neurotumor cell line. Cancer Lett. 187 (2002) 163-168
198. Cho S., and Dawson G. Palmitoyl protein thioesterase 1 protects against apoptosis mediated by Ras-Akt-caspase pathway in neuroblastoma cells. J. Neurochem. 74 (2000) 1478-1488
199. Korey C.A., and MacDonald M.E. An over-expression system for characterizing Ppt1 function in Drosophila. BMC Neurosci. 4 (2003) 30
200. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82 (1995) 949-957
201. Zhong N. Neuronal ceroid lipofuscinoses and possible pathogenic mechanism. Mol. Genet. Metab. 71 (2000) 195-206
202. Puranam K., Qian W.H., Nikbakht K., Venable M., Obeid L., Hannun Y., and Boustany R.M. Upregulation of Bcl-2 and elevation of ceramide in Batten disease. Neuropediatrics 28 (1997) 37-41
203. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., and Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 66 (1999) 294-308
204. Rylova S.N., Amalfitano A., Persaud-Sawin D.A., Guo W.X., Chang J., Jansen P.J., Proia A.D., and Boustany R.M. The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 62 (2002) 801-808
205. Persaud-Sawin D.A., VanDongen A., and Boustany R.M. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum. Mol. Genet. 11 (2002) 2129-2142
206. Kornfeld S., and Mellman I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5 (1989) 483-525
207. Chen J.W., Madamanchi N., Madamanchi N.R., Trier T.T., and Keherly M.J. Lamp-1 is upregulated in human glioblastoma cell lines induced to undergo apoptosis. J. Biomed. Sci. 8 (2001) 365-374
208. Cuervo A.M., Mann L., Bonten E.J., d'Azzo A., and Dice J.F. Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. EMBO J. 22 (2003) 47-59
209. Gonzalez-Polo R.A., Boya P., Pauleau A.L., Jalil A., Larochette N., Souquere S., Eskelinen E.L., Pierron G., Saftig P., and Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J. Cell Sci. 118 (2005) 3091-3102
210. Felbor U., Kessler B., Mothes W., Goebel H.H., Ploegh H.L., Bronson R.T., and Olsen B.R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7883-7888
211. Saftig P., Hetman M., Schmahl W., Weber K., Heine L., Mossmann H., Koster A., Hess B., Evers M., von Figura K., et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14 (1995) 3599-3608
212. Nakanishi H., Zhang J., Koike M., Nishioku T., Okamoto Y., Kominami E., von Figura K., Peters C., Yamamoto K., Saftig P., and Uchiyama Y. Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J. Neurosci. 21 (2001) 7526-7533
213. Koike M., Shibata M., Ohsawa Y., Nakanishi H., Koga T., Kametaka S., Waguri S., Momoi T., Kominami E., Peters C., Figura K., Saftig P., and Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol. Cell. Neurosci. 22 (2003) 146-161
214. Rakoczy P.E., Zhang D., Robertson T., Barnett N.L., Papadimitriou J., Constable I.J., and Lai C.M. Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model. Am. J. Pathol. 161 (2002) 1515-1524
215. Tyynela J., Sohar I., Sleat D.E., Gin R.M., Donnelly R.J., Baumann M., Haltia M., and Lobel P. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 19 (2000) 2786-2792
216. Gupta P., Soyombo A.A., Atashband A., Wisniewski K.E., Shelton J.M., Richardson J.A., Hammer R.E., and Hofmann S.L. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13566-13571
217. Otterbach B., and Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81 (1995) 1053-1061
218. Horinouchi K., Erlich S., Perl D.P., Ferlinz K., Bisgaier C.L., Sandhoff K., Desnick R.J., Stewart C.L., and Schuchman E.H. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 10 (1995) 288-293
219. Berchem G., Glondu M., Gleizes M., Brouillet J.P., Vignon F., Garcia M., and Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21 (2002) 5951-5955
220. Visscher D.W., Sarkar F., LoRusso P., Sakr W., Ottosen S., Wykes S., and Crissman J.D. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod. Pathol. 6 (1993) 302-306
221. Bremer C., Tung C.H., Bogdanov Jr. A., and Weissleder R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 222 (2002) 814-818
222. Kielan W., Suzanowicz J., SiewiNski M., Saleh Y., Janocha A., Skalski A., and Tarnawa R. Evaluation of changes in the activity of proteolytic enzymes and their inhibitors in the processes that accompany the growth of gastric cancer. Gastric Cancer 7 (2004) 17-23
223. Nomura T., and Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest. 52 (2005) 1-9
224. Schwartz M.K. Tissue cathepsins as tumor markers. Clin. Chim. Acta 237 (1995) 67-78
225. Kirschke H. Lysosomal cysteine peptidases and malignant tumours. Adv. Exp. Med. Biol. 421 (1997) 253-257
226. Lah T.T., and Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379 (1998) 125-130
227. Kos J., Werle B., Lah T., and Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 15 (2000) 84-89
228. Rochefort H., Garcia M., Glondu M., Laurent V., Liaudet E., Rey J.M., and Roger P. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin. Chim. Acta 291 (2000) 157-170
229. Berdowska I. Cysteine proteases as disease markers. Clin. Chim. Acta 342 (2004) 41-69
230. Barbi G.P., Margallo E., Margiocco M., Paganuzzi M., Marroni P., Costanzi B., Gatteschi B., Tanara G., Spina B., and Nicolo G. Evaluation of cathepsin D as prognostic predictor in breast cancer. Oncology 51 (1994) 329-333
231. Thomssen C., Schmitt M., Goretzki L., Oppelt P., Pache L., Dettmar P., Janicke F., and Graeff H. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin. Cancer Res. 1 (1995) 741-746
232. Losch A., Schindl M., Kohlberger P., Lahodny J., Breitenecker G., Horvat R., and Birner P. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol. Oncol. 92 (2004) 545-552
233. Musumarra G., Barresi V., Condorelli D.F., and Scire S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol. Chem. 384 (2003) 321-327
234. Kos J., and Lah T.T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol. Rep. 5 (1998) 1349-1361
235. Koblinski J.E., Ahram M., and Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291 (2000) 113-135
236. Jedeszko C., and Sloane B.F. Cysteine cathepsins in human cancer. Biol. Chem. 385 (2004) 1017-1027
237. Journet A., and Ferro M. The potentials of MS-based subproteomic approaches in medical science: the case of lysosomes and breast cancer. Mass Spectrom. Rev. 23 (2004) 393-442
238. Isidoro C., Demoz M., De Stefanis D., Baccino F.M., Hasilik A., and Bonelli G. Differential targeting and processing of procathepsin D in normal and transformed murine 3T3 fibroblasts. Int. J. Cancer 70 (1997) 310-314
239. Nishimura Y., Sameni M., and Sloane B.F. Malignant transformation alters intracellular trafficking of lysosomal cathepsin D in human breast epithelial cells. Pathol. Oncol. Res. 4 (1998) 283-296
240. Demoz M., Castino R., Dragonetti A., Raiteri E., Baccino F.M., and Isidoro C. Transformation by oncogenic ras-p21 alters the processing and subcellular localization of the lysosomal protease cathepsin D. J. Cell. Biochem. 73 (1999) 370-378
241. Donatien P.D., Diment S.L., Boissy R.E., and Orlow S.J. Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-rasHa oncogene. Int. J. Cancer 66 (1996) 557-563
242. Sloane B.F., Moin K., Sameni M., Tait L.R., Rozhin J., and Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci. 107 Pt. 2 (1994) 373-384
243. Weber E., Gunther D., Laube F., Wiederanders B., and Kirschke H. Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth. J. Cancer Res. Clin. Oncol. 120 (1994) 564-567
244. Kirschke H., Eerola R., Hopsu-Havu V.K., Bromme D., and Vuorio E. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur. J. Cancer 36 (2000) 787-795
245. Keppler D., Sameni M., Moin K., Mikkelsen T., Diglio C.A., and Sloane B.F. Tumor progression and angiogenesis: cathepsin B and Co. Biochem. Cell. Biol. 74 (1996) 799-810
246. Yanamandra N., Gumidyala K.V., Waldron K.G., Gujrati M., Olivero W.C., Dinh D.H., Rao J.S., and Mohanam S. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23 (2004) 2224-2230
247. Kruszewski W.J., Rzepko R., Wojtacki J., Skokowski J., Kopacz A., Jaskiewicz K., and Drucis K. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 51 (2004) 38-43
248. Kostoulas G., Lang A., Nagase H., and Baici A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 455 (1999) 286-290
249. Tzanakakis G.N., Margioris A.N., Tsatsakis A.M., and Vezeridis M.P. The metastatic potential of human pancreatic cell lines in the liver of nude mice correlates well with cathepsin B activity. Int. J. Gastrointest. Cancer 34 (2003) 27-38
250. Dohchin A., Suzuki J.I., Seki H., Masutani M., Shiroto H., and Kawakami Y. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer 89 (2000) 482-487
251. Coulibaly S., Schwihla H., Abrahamson M., Albini A., Cerni C., Clark J.L., Ng K.M., Katunuma N., Schlappack O., Glossl J., and Mach L. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int. J. Cancer 83 (1999) 526-531
252. Bervar A., Zajc I., Sever N., Katunuma N., Sloane B.F., and Lah T.T. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol. Chem. 384 (2003) 447-455
253. Gondi C.S., Lakka S.S., Dinh D.H., Olivero W.C., Gujrati M., and Rao J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23 (2004) 8486-8496
254. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R., and Rao J.S. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 64 (2004) 4069-4077
255. Lakka S.S., Gondi C.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., and Rao J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23 (2004) 4681-4689
256. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.Y., Greenbaum D.C., Hager J.H., Bogyo M., and Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5 (2004) 443-453
257. Frade R., Rodrigues-Lima F., Huang S., Xie K., Guillaume N., and Bar-Eli M. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 58 (1998) 2733-2736
258. Rousselet N., Mills L., Jean D., Tellez C., Bar-Eli M., and Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 64 (2004) 146-151
259. Colella R., Goodwyn E., and Gopal P. Increased cell density decreases cysteine proteinase inhibitor activity and increases invasive ability of two prostate tumor cell lines. Cancer Lett. 185 (2002) 163-172
260. Colella R., and Casey S.F. Decreased activity of cathepsins L+B and decreased invasive ability of PC3 prostate cancer cells. Biotech. Histochem. 78 (2003) 101-108
261. Shridhar R., Zhang J., Song J., Booth B.A., Kevil C.G., Sotiropoulou G., Sloane B.F., and Keppler D. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23 (2004) 2206-2215
262. Zhang J., Shridhar R., Dai Q., Song J., Barlow S.C., Yin L., Sloane B.F., Miller F.R., Meschonat C., Li B.D., Abreo F., and Keppler D. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 64 (2004) 6957-6964
263. Nazeer T., Malfetano J.H., Rosano T.G., and Ross J.S. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am. J. Clin. Pathol. 97 (1992) 764-769
264. Liaudet E., Derocq D., Rochefort H., and Garcia M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ. 6 (1995) 1045-1052
265. Garcia M., Platet N., Liaudet E., Laurent V., Derocq D., Brouillet J.P., and Rochefort H. Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem. Cells 14 (1996) 642-650
266. Glondu M., Liaudet-Coopman E., Derocq D., Platet N., Rochefort H., and Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21 (2002) 5127-5134
267. Yamada T., De Souza A.T., Finkelstein S., and Jirtle R.L. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10351-10355
268. De Souza A.T., Hankins G.R., Washington M.K., Orton T.C., and Jirtle R.L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11 (1995) 447-449
269. Kong F.M., Anscher M.S., Washington M.K., Killian J.K., and Jirtle R.L. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19 (2000) 1572-1578
270. Ouyang H., Shiwaku H.O., Hagiwara H., Miura K., Abe T., Kato Y., Ohtani H., Shiiba K., Souza R.F., Meltzer S.J., and Horii A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res. 57 (1997) 1851-1854
271. Souza R.F., Appel R., Yin J., Wang S., Smolinski K.N., Abraham J.M., Zou T.T., Shi Y.Q., Lei J., Cottrell J., Cymes K., Biden K., Simms L., Leggett B., Lynch P.M., Frazier M., Powell S.M., Harpaz N., Sugimura H., Young J., and Meltzer S.J. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet. 14 (1996) 255-257
272. Caligo M.A., Ghimenti C., Sensi E., Marchetti A., Bertacca G., Giulianotti P.G., Fornaciari G., and Bevilacqua G. Microsatellite alterations and K-ras, TGFbetaRII, IGFRII and bax mutations in sporadic cancers of the gastrointestinal tract. Oncol. Rep. 7 (2000) 1371-1375
273. Calin G.A., Gafa R., Tibiletti M.G., Herlea V., Becheanu G., Cavazzini L., Barbanti-Brodano G., Nenci I., Negrini M., and Lanza G. Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int. J. Cancer 89 (2000) 230-235
274. Hankins G.R., De Souza A.T., Bentley R.C., Patel M.R., Marks J.R., Iglehart J.D., and Jirtle R.L. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12 (1996) 2003-2009
275. Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., and Scherneck S. Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines. Genes Chromosomes Cancer 37 (2003) 29-35
276. Jamieson T.A., Brizel D.M., Killian J.K., Oka Y., Jang H.S., Fu X., Clough R.W., Vollmer R.T., Anscher M.S., and Jirtle R.L. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer 3 (2003) 4
277. Li J., and Sahagian G.G. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 23 (2004) 9359-9368
278. Souza R.F., Wang S., Thakar M., Smolinski K.N., Yin J., Zou T.T., Kong D., Abraham J.M., Toretsky J.A., and Meltzer S.J. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 18 (1999) 4063-4068
279. O'Gorman D.B., Weiss J., Hettiaratchi A., Firth S.M., and Scott C.D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143 (2002) 4287-4294
280. Lee J.S., Weiss J., Martin J.L., and Scott C.D. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer 107 (2003) 564-570
281. O'Gorman D.B., Costello M., Weiss J., Firth S.M., and Scott C.D. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res. 59 (1999) 5692-5694
282. Chen Z., Ge Y., Landman N., and Kang J.X. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2 (2002) 18
283. Jirtle R.L., Hankins G.R., Reisenbichler H., and Boyer I.J. Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis 15 (1994) 1473-1478
284. Pierce Jr. D.F., Gorska A.E., Chytil A., Meise K.S., Page D.L., Coffey Jr. R.J., and Moses H.L. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4254-4258
285. Sue S.R., Chari R.S., Kong F.M., Mills J.J., Fine R.L., Jirtle R.L., and Meyers W.C. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann. Surg. 222 (1995) 171-178
286. Wang S., Souza R.F., Kong D., Yin J., Smolinski K.N., Zou T.T., Frank T., Young J., Flanders K.C., Sugimura H., Abraham J.M., and Meltzer S.J. Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res. 57 (1997) 2543-2546
287. Osipo C., Dorman S., and Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp. Cell Res. 264 (2001) 388-396
288. Bates P., Fisher R., Ward A., Richardson L., Hill D.J., and Graham C.F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer 72 (1995) 1189-1193
289. Lorenzo K., Ton P., Clark J.L., Coulibaly S., and Mach L. Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin-like growth factor II receptor. Cancer Res. 60 (2000) 4070-4076
290. Ogier-Denis E., and Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochim. Biophys. Acta 1603 (2003) 113-128
291. Alva A.S., Gultekin S.H., and Baehrecke E.H. Autophagy in human tumors: cell survival or death?. Cell Death Differ. 11 (2004) 1046-1048
292. Edinger A.L., and Thompson C.B. Defective autophagy leads to cancer. Cancer Cell 4 (2003) 422-424
293. Meijer A.J., and Codogno P. Regulation and role of autophagy in mammalian cells. Int. J. Biochem. Cell Biol. 36 (2004) 2445-2462
294. Aita V.M., Liang X.H., Murty V.V., Pincus D.L., Yu W., Cayanis E., Kalachikov S., Gilliam T.C., and Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59 (1999) 59-65
295. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., and Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402 (1999) 672-676
296. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.L., Mizushima N., Ohsumi Y., Cattoretti G., and Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 112 (2003) 1809-1820
297. Yue Z., Jin S., Yang C., Levine A.J., and Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15077-15082
298. Kihara A., Kabeya Y., Ohsumi Y., and Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2 (2001) 330-335
299. Furuya N., Yu J., Byfield M., and Levine B. The evolutionary conserved domain of Beclin 1 is required for Vps34 binding, autophagy, and tumor suppressor function. Autophagy 1 (2005) 46-52
300. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
301. Maehama T., Taylor G.S., and Dixon J.E. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70 (2001) 247-279
302. Arico S., Petiot A., Bauvy C., Dubbelhuis P.F., Meijer A.J., Codogno P., and Ogier-Denis E. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 276 (2001) 35243-35246
303. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev., Cancer 4 (2004) 604-616
304. Daido S., Kanzawa T., Yamamoto A., Takeuchi H., Kondo Y., and Kondo S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res. 64 (2004) 4286-4293
305. Brunk U.T., and Svensson I. Oxidative stress, growth factor starvation and Fas activation may all cause apoptosis through lysosomal leak. Redox Rep. 4 (1999) 3-11
306. Roberg K., Johansson U., and Ollinger K. Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress. Free Radic. Biol. Med. 27 (1999) 1228-1237
307. Li W., Yuan X., Nordgren G., Dalen H., Dubowchik G.M., Firestone R.A., and Brunk U.T. Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett. 470 (2000) 35-39
308. Roberg K. Relocalization of cathepsin D and cytochrome c early in apoptosis revealed by immunoelectron microscopy. Lab. Invest. 81 (2001) 149-158
309. Werneburg N.W., Guicciardi M.E., Bronk S.F., and Gores G.J. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am. J. Physiol.: Gastrointest. Liver Physiol. 283 (2002) G947-G956
310. Bidere N., Lorenzo H.K., Carmona S., Laforge M., Harper F., Dumont C., and Senik A. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem. 278 (2003) 31401-31411
311. Erdal H., Berndtsson M., Castro J., Brunk U., Shoshan M.C., and Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 192-197
312. Turk B., Bieth J.G., Bjork I., Dolenc I., Turk D., Cimerman N., Kos J., Colic A., Stoka V., and Turk V. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe-Seyler 376 (1995) 225-230
313. Turk B., Dolenc I., Turk V., and Bieth J.G. Kinetics of the pH-induced inactivation of human cathepsin L. Biochemistry 32 (1993) 375-380
314. Yuan X.M., Li W., Dalen H., Lotem J., Kama R., Sachs L., and Brunk U.T. Lysosomal destabilization in p53-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6286-6291
315. Schutze S., Machleidt T., Adam D., Schwandner R., Wiegmann K., Kruse M.L., Heinrich M., Wickel M., and Kronke M. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J. Biol. Chem. 274 (1999) 10203-10212
316. Werneburg N., Guicciardi M.E., Yin X.M., and Gores G.J. Tumor Necrosis Factor-mediated lysosomal permeabilization is FAN and caspase 8/Bid-dependent. Am. J. Physiol.: Gastrointest. Liver Physiol. 287 (2004) G436-G443
317. Kagedal K., Johansson A.C., Johansson U., Heimlich G., Roberg K., Wang N.S., Jurgensmeier J.M., and Ollinger K. Lysosomal membrane permeabilization during apoptosis-involvement of Bax?. Int. J. Exp. Pathol. 86 (2005) 309-321
318. Guicciardi M.E., Bronk S.F., Werneburg N.W., Yin X.M., and Gores G.J. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. Gastroenterology 129 (2005) 269-284
319. Zhao M., Eaton J.W., and Brunk U.T. Protection against oxidant-mediated lysosomal rupture: a new anti-apoptotic activity of Bcl-2?. FEBS Lett. 485 (2000) 104-108
320. Zhao M., Eaton J.W., and Brunk U.T. Bcl-2 phosphorylation is required for inhibition of oxidative stress-induced lysosomal leak and ensuing apoptosis. FEBS Lett. 509 (2001) 405-412
321. 2 is a consequence of lysosomal rupture. Biochem. J. 356 (2001) 549-555
322. Dare E., Li W., Zhivotovsky B., Yuan X., and Ceccatelli S. Methylmercury and H(2)O(2) provoke lysosomal damage in human astrocytoma D384 cells followed by apoptosis. Free Radic. Biol. Med. 30 (2001) 1347-1356
323. Persson H.L., Yu Z., Tirosh O., Eaton J.W., and Brunk U.T. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic. Biol. Med. 34 (2003) 1295-1305
324. Brun A., and Brunk U. Histochemical indications for lysosomal localization of heavy metals in normal rat brain and liver. J. Histochem. Cytochem. 18 (1970) 820-827
325. Zdolsek J., Zhang H., Roberg K., and Brunk U. H2O2-mediated damage to lysosomal membranes of J-774 cells. Free Radic. Res. Commun. 18 (1993) 71-85
326. Ollinger K., and Brunk U.T. Cellular injury induced by oxidative stress is mediated through lysosomal damage. Free Radic. Biol. Med. 19 (1995) 565-574
327. Manna S.K., Zhang H.J., Yan T., Oberley L.W., and Aggarwal B.B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J. Biol. Chem. 273 (1998) 13245-13254
328. Wang J.H., Redmond H.P., Watson R.W., and Bouchier-Hayes D. Induction of human endothelial cell apoptosis requires both heat shock and oxidative stress responses. Am. J. Physiol. 272 (1997) C1543-C1551
329. Ferri K.F., and Kroemer G. Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3 (2001) E255-E263
330. Zhao M., Antunes F., Eaton J.W., and Brunk U.T. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur. J. Biochem. 270 (2003) 3778-3786
331. Nylandsted J., Gyrd-Hansen M., Danielewicz A., Fehrenbacher N., Lademann U., Hoyer-Hansen M., Weber E., Multhoff G., Rohde M., and Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med. 200 (2004) 425-435
332. Liu N., Raja S.M., Zazzeroni F., Metkar S.S., Shah R., Zhang M., Wang Y., Bromme D., Russin W.A., Lee J.C., Peter M.E., Froelich C.J., Franzoso G., and Ashton-Rickardt P.G. NF-kappaB protects from the lysosomal pathway of cell death. EMBO J. 22 (2003) 5313-5322
333. Hirpara J.L., Clement M.V., and Pervaiz S. Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J. Biol. Chem. 276 (2001) 514-521
334. Ahmad K.A., Iskandar K.B., Hirpara J.L., Clement M.V., and Pervaiz S. Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res. 64 (2004) 7867-7878
335. Haq R., and Zanke B. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev. 17 (1998) 233-239
336. Zanke B.W., Lee C., Arab S., and Tannock I.F. Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibition. Cancer Res. 58 (1998) 2801-2808
337. 2+ and pH. Biochem. Biophys. Res. Commun. 186 (1992) 782-789
338. Barry M.A., and Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch. Biochem. Biophys. 300 (1993) 440-450
339. Altairac S., Zeggai S., Perani P., Courtois Y., and Torriglia A. Apoptosis induced by Na+/H+ antiport inhibition activates the LEI/L-DNase II pathway. Cell Death Differ. 10 (2003) 548-557
340. Cirman T., Oresic K., Mazovec G.D., Turk V., Reed J.C., Myers R.M., Salvesen G.S., and Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem. 279 (2004) 3578-3587
341. Stoka V., Turk B., Schendel S.L., Kim T.H., Cirman T., Snipas S.J., Ellerby L.M., Bredesen D., Freeze H., Abrahamson M., Bromme D., Krajewski S., Reed J.C., Yin X.M., Turk V., and Salvesen G.S. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem. 276 (2001) 3149-3157
342. Houseweart M.K., Vilaythong A., Yin X.M., Turk B., Noebels J.L., and Myers R.M. Apoptosis caused by cathepsins does not require Bid signaling in an in vivo model of progressive myoclonus epilepsy (EPM1). Cell Death Differ. 10 (2003) 1329-1335
343. Dietrich N., Thastrup J., Holmberg C., Gyrd-Hansen M., Fehrenbacher N., Lademann U., Lerdrup M., Herdegen T., Jaattela M., and Kallunki T. JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ. 11 (2004) 301-313
344. Boya P., Andreau K., Poncet D., Zamzami N., Perfettini J.L., Metivier D., Ojcius D.M., Jaattela M., and Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med. 197 (2003) 1323-1334
345. Schotte P., Van Criekinge W., Van de Craen M., Van Loo G., Desmedt M., Grooten J., Cornelissen M., De Ridder L., Vandekerckhove J., Fiers W., Vandenabeele P., and Beyaert R. Cathepsin B-mediated activation of the proinflammatory caspase-11. Biochem. Biophys. Res. Commun. 251 (1998) 379-387
346. Vancompernolle K., Van Herreweghe F., Pynaert G., Van de Craen M., De Vos K., Totty N., Sterling A., Fiers W., Vandenabeele P., and Grooten J. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett. 438 (1998) 150-158
347. Ishisaka R., Utsumi T., Kanno T., Arita K., Katunuma N., Akiyama J., and Utsumi K. Participation of a cathepsin L-type protease in the activation of caspase-3. Cell Struct. Funct. 24 (1999) 465-470
348. Jaattela M. Programmed cell death: many ways for cells to die decently. Ann. Med. 34 (2002) 480-488
349. Fehrenbacher N., and Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res. 65 (2005) 2993-2995
350. Kondo Y., Kanzawa T., Sawaya R., and Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev., Cancer 5 (2005) 726-734
351. Boesen-de Cock J.G., Tepper A.D., de Vries E., van Blitterswijk W.J., and Borst J. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J. Biol. Chem. 274 (1999) 14255-14261
352. Huang C., Ma W., Ding M., Bowden G.T., and Dong Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J. Biol. Chem. 272 (1997) 27753-27757
353. Woodle E.S., Smith D.M., Bluestone J.A., Kirkman III W.M., Green D.R., and Skowronski E.W. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J. Immunol. 158 (1997) 2156-2164
354. Lozano J., Menendez S., Morales A., Ehleiter D., Liao W.C., Wagman R., Haimovitz-Friedman A., Fuks Z., and Kolesnick R. Cell autonomous apoptosis defects in acid sphingomyelinase knockout fibroblasts. J. Biol. Chem. 276 (2001) 442-448
355. Gupta S., Natarajan R., Payne S.G., Studer E.J., Spiegel S., Dent P., and Hylemon P.B. Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J. Biol. Chem. 279 (2004) 5821-5828
356. Kirschnek S., Paris F., Weller M., Grassme H., Ferlinz K., Riehle A., Fuks Z., Kolesnick R., and Gulbins E. CD95-mediated apoptosis in vivo involves acid sphingomyelinase. J. Biol. Chem. 275 (2000) 27316-27323
357. Paris F., Grassme H., Cremesti A., Zager J., Fong Y., Haimovitz-Friedman A., Fuks Z., Gulbins E., and Kolesnick R. Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes. J. Biol. Chem. 276 (2001) 8297-8305
358. Otala M., Pentikainen M.O., Matikainen T., Suomalainen L., Hakala J.K., Perez G.I., Tenhunen M., Erkkila K., Kovanen P., Parvinen M., and Dunkel L. Effects of acid sphingomyelinase deficiency on male germ cell development and programmed cell death. Biol. Reprod. 72 (2005) 86-96
359. Scheel-Toellner D., Wang K., Craddock R., Webb P.R., McGettrick H.M., Assi L.K., Parkes N., Clough L.E., Gulbins E., Salmon M., and Lord J.M. Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood 104 (2004) 2557-2564
360. Lang K.S., Myssina S., Brand V., Sandu C., Lang P.A., Berchtold S., Huber S.M., Lang F., and Wieder T. Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ. 11 (2004) 231-243
361. Esen M., Schreiner B., Jendrossek V., Lang F., Fassbender K., Grassme H., and Gulbins E. Mechanisms of Staphylococcus aureus induced apoptosis of human endothelial cells. Apoptosis 6 (2001) 431-439
362. Herr I., Wilhelm D., Bohler T., Angel P., and Debatin K.M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16 (1997) 6200-6208
363. Paquet C., Sane A.T., Beauchemin M., and Bertrand R. Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 19 (2005) 784-791
364. Ostenfeld M.S., Fehrenbacher N., Hoyer-Hansen M., Thomsen C., Farkas T., and Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 65 (2005) 8975-8983
365. Hara S., Nakashima S., Kiyono T., Sawada M., Yoshimura S., Iwama T., Banno Y., Shinoda J., and Sakai N. p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ. 11 (2004) 853-861
366. Batra S., Reynolds C.P., and Maurer B.J. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res. 64 (2004) 5415-5424
367. Yu Z., Li W., Hillman J., and Brunk U.T. Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-aminopropanal. Brain Res. 1016 (2004) 163-169
368. Li W., Yuan X.M., Ivanova S., Tracey K.J., Eaton J.W., and Brunk U.T. 3-Aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem. J. 371 (2003) 429-436
369. Caruso J.A., Mathieu P.A., Joiakim A., Leeson B., Kessel D., Sloane B.F., and Reiners Jr. J.J. Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents. Mol. Pharmacol. 65 (2004) 1016-1028
370. Nakashima S., Hiraku Y., Tada-Oikawa S., Hishita T., Gabazza E.C., Tamaki S., Imoto I., Adachi Y., and Kawanishi S. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J. Biochem. (Tokyo) 134 (2003) 359-364
371. Matroule J.Y., Carthy C.M., Granville D.J., Jolois O., Hunt D.W., and Piette J. Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-A methylester photosensitization. Oncogene 20 (2001) 4070-4084
372. Neuzil J., Svensson I., Weber T., Weber C., and Brunk U.T. Alpha-tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Lett. 445 (1999) 295-300
373. Chi S., Kitanaka C., Noguchi K., Mochizuki T., Nagashima Y., Shirouzu M., Fujita H., Yoshida M., Chen W., Asai A., Himeno M., Yokoyama S., and Kuchino Y. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 18 (1999) 2281-2290
374. Levicar N., Strojnik T., Kos J., Dewey R.A., Pilkington G.J., and Lah T.T. Lysosomal enzymes, cathepsins in brain tumour invasion. J. Neuro-Oncol. 58 (2002) 21-32
375. Pena L.A., Fuks Z., and Kolesnick R.N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res. 60 (2000) 321-327
376. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., and Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
377. Li Y.Q., Chen P., Haimovitz-Friedman A., Reilly R.M., and Wong C.S. Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res. 63 (2003) 5950-5956
378. Morita Y., Perez G.I., Paris F., Miranda S.R., Ehleiter D., Haimovitz-Friedman A., Fuks Z., Xie Z., Reed J.C., Schuchman E.H., Kolesnick R.N., and Tilly J.L. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat. Med. 6 (2000) 1109-1114
379. Takai Y., Canning J., Perez G.I., Pru J.K., Schlezinger J.J., Sherr D.H., Kolesnick R.N., Yuan J., Flavell R.A., Korsmeyer S.J., and Tilly J.L. Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo. Endocrinology 144 (2003) 69-74
380. Garcia-Ruiz C., Colell A., Mari M., Morales A., Calvo M., Enrich C., and Fernandez-Checa J.C. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J. Clin. Invest. 111 (2003) 197-208
381. Yu Z.F., Nikolova-Karakashian M., Zhou D., Cheng G., Schuchman E.H., and Mattson M.P. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J. Mol. Neurosci. 15 (2000) 85-97
382. Grassme H., Jendrossek V., Riehle A., von Kurthy G., Berger J., Schwarz H., Weller M., Kolesnick R., and Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9 (2003) 322-330
383. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., and Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 (2001) 293-297